Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of OXURION N.V.
Analyst Grade Summary
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
1
0
0
0
No Price
Closing Price XBRU 28.04.2026:
0,004 EUR
28.04.2026 11:32
Current Prices from OXURION N.V.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
EURONEXT - EURONEXT BRUSSELS
OXUR.BR
EUR
28.04.2026 11:32
0,004 EUR
-0,0002 EUR
-5,00 %
Share Float & Liquidity
Free Float83,83 %
Shares Float58,76 M
Shares Outstanding70,1 M
Company Profile for OXURION N.V. Share
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
